Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Update

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 58,900 shares, a decline of 91.6% from the October 31st total of 702,600 shares. Based on an average daily volume of 1,540,000 shares, the short-interest ratio is presently 0.0 days. Approximately 2.6% of the shares of the company are short sold.

Shuttle Pharmaceuticals Stock Performance

Shuttle Pharmaceuticals stock traded down $0.04 during trading hours on Wednesday, hitting $0.83. The stock had a trading volume of 32,053 shares, compared to its average volume of 455,212. Shuttle Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $4.95. The company’s 50-day simple moving average is $1.26. The stock has a market cap of $3.05 million, a P/E ratio of -0.20 and a beta of -1.32.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.96) EPS for the quarter.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .